-
LABT share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of LABT shares has decreased $0.15 since the market last closed. This is a 28.54% drop.
-
Closed at $0.39.
The stock has since dropped $0.01 in after-hours trading.
Key terms
About LABT
Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.
-
Market cap: $915.41K
A market capitalization up to $300 million places LABT in the micro-capitalization category.
Key terms
Smart score
Latest LABT news
No recent press releases are available for LABT
LABT Financials
-
LABT total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: -$3.85M (1Y), -$3.77M (Q2)
Net Income increased 20.76% since last year and decreased 308.54% since last quarter.
-
Earnings per share: -$8.40 (1Y), -$1.74 (Q2)
EPS decreased 20.0% since last year and increased 13.06% since last quarter.
Key terms
LABT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LABT Competitors
-
How competitors are chosen
LABT's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $915.41K
A market capitalization up to $300 million places LABT in the micro-capitalization category.
